Skip to main content
Sign In

Lupus Research Studies

​The Division of Rheumatology strives to understand more about lupus through research.  Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 
​Study Name Brief Description​ Basic Eligibility​ Criteria Contact​
​RSLV-132 Use of new (unapproved) protein-based medication.  This study includes a placebo group. Moderately severe active skin lupus. ​303-724-0581, 303-724-7518 or email
​CALIBRATE ​Use of a combination of medications approved for rheumatoid arthritis and systemic lupus to treat lupus that has involved the kidney.  This study does not include a placebo group. Individuals with class III or IV lupus kidney disease.  Patients must have previously been treated with either cyclophosphamide or mycophenolate. ​​303-724-0581, 303-724-7518 or email
​TULIP-LN ​Use of anti-type I INF receptor in lupus nephritis. ​Proteinura/Urine pr/Cr >1
Background steriods and MMF
​​303-724-0581, 303-724-7518 or email​​
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length.  A visit to determine an individuals eligibility may be required.  A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.